Docosahexaenoic acid and its derivative neuroprotectin d1 display neuroprotective properties in the retina, brain and central nervous system

Nestle Nutrition Institute Workshop Series

Volumn 77, Issue , 2013, Pages 121-131

  Bazan, Nicolas G ^a   Calandria, Jorgelina M ^a   Gordon, William C ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; PROTECTIN D1;

ANIMAL; BRAIN; BRAIN DISEASE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; EPILEPSY; HUMAN; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; RETINA; RETINA DEGENERATION;

ANIMALS; BRAIN; BRAIN DISEASES; BRAIN ISCHEMIA; DOCOSAHEXAENOIC ACIDS; EPILEPSY; HUMANS; OXIDATIVE STRESS; RETINA; RETINAL DEGENERATION; STROKE;

EID: 84899470675     PISSN: 16642147     EISSN: 16642155     Source Type: Book Series    
DOI: 10.1159/000351395     Document Type: Conference Paper

References (64)

1. Serhan CN, Hong S, Gronert K, et al: Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002; 196: 1025-1037.
2. Bazan NG, Birkle DL, Reddy TS: Docosahexaenoic acid (22: 6, n-3) is metabolized to lipoxygenase reaction products in the retina. Biochem Biophys Res Commun 1984; 125: 741-747.
3. Bazan NG: Homeostatic regulation of photoreceptor cell integrity: significance of the potent mediator neuroprotectin D1 biosynthesized from docosahexaenoic acid: the Proctor Lecture. Invest Ophthalmol Vis Sci 2007; 48: 4866-4881.
4. Bazan NG, Birkle DL, Reddy TS: Biochemical and nutritional aspects of the metabolism of polyunsaturated fatty acids and phospholipids in experimental models of retinal degeneration; in LaVail MM, Hollyfield JG, Anderson RE (eds): Retinal Degeneration: Experimental and Clinical Studies. New York, Liss, 1985, pp 159-187.
5. Marcheselli VL, Hong S, Lukiw WJ, et al: Novel docosanoids inhibit brain ischemiareperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 2003; 278: 43807-43817.
6. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG: Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA 2004; 101: 8491-8496.
7. Lukiw WJ, Cui J, Marcheselli VL, et al: A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 2005; 115: 2774-2783.
8. Schwab JM, Chiang N, Arita M, Serhan CN: Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007; 447: 869-874.
9. Serhan CN: Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol 2007; 25: 101-137.
10. Aveldano MI, Bazan NG: Displacement into incubation medium by albumin of highly unsaturated retina free fatty acids arising from membrane lipids. FEBS Lett 1974; 40: 53-56.
11. Aveldano MI, Bazan NG: Differential lipid deacylation during brain ischemia in a homeotherm and a poikilotherm. Content and composition of free fatty acids and triacylglycerols. Brain Res 1975; 100: 99-110.
12. Bazan NG: Synaptic lipid signaling: significance of polyunsaturated fatty acids and platelet-activating factor. J Lipid Res 2003; 44: 2221-2233.
13. Horrocks LA, Farooqui AA: NMDA receptor-stimulated release of arachidonic acid: mechanisms for the Bazan effect; in Municio AM, Miras-Portugal MT (eds): Cell Signal Transduction, Second Messengers, and Protein Phosphorylation in Health and Disease. New York, Plenum, 1994, pp 113-128.
14. Sun GY, Xu J, Jensen MD, Simonyi A: Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J Lipid Res 2004; 45: 205-213.
15. Reddy TS, Bazan NG: Activation of polyunsaturated fatty acids by rat tissues in vitro. Lipids 1984; 19: 987-989.
16. Reddy TS, Bazan NG: Synthesis of arachidonoyl coenzyme A and docosahexaenoyl coenzyme A in retina. Curr Eye Res 1984; 3: 1225-1232.
17. Reddy TS, Bazan NG: Synthesis of arachidonoyl coenzyme A and docosahexaenoyl coenzyme A in synaptic plasma membranes of cerebrum and microsomes of cerebrum, cerebellum, and brain stem of rat brain. J Neurosci Res 1985; 13: 381-390.
18. Reddy TS, Bazan NG: Synthesis of docosahexaenoyl-, arachidonoyl-and palmitoyl-coenzyme A in ocular tissues. Exp Eye Res 1985b;41: 87-95.
19. Calandria JM, Marcheselli VL, Mukherjee PK, et al: Selective survival rescue in 15-lipoxygenase-1-deficient retinal pigment epithelial cells by the novel docosahexaenoic acid-derived mediator, neuroprotectin D1. J Biol Chem 2009; 284: 17877-17882.
20. Mukherjee PK, Marcheselli VL, de Rivero Vaccari JC, et al: Photoreceptor outer segment phagocytosis attenuates oxidative stress-induced apoptosis with concomitant neuroprotectin D1 synthesis. Proc Natl Acad Sci USA 2007; 104: 13158-13163.
21. Qin Q, Patil KA, Gronert K, Sharma SC: Neuroprotectin D1 inhibits retinal ganglion cell death following axotomy. Prostaglandins Leukot Essent Fatty Acids 2008; 79: 201-207.
22. González-Périz A, Horrillo R, Ferré N, et al: Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 2009; 23: 1946-1957.
23. Zhao Y, Calon F, Julien C, et al: Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase-and PPARγ-mediated mechanisms in Alzheimer's disease models. PLoS One 2011; 6:e15816.
24. Lim GP, Calon F, Morihara T, et al: A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 2005; 25: 3032-3040.
25. Oksman M, Iivonen H, Hogyes E, et al: Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol Dis 2006; 23: 563-572.
26. Sahlin C, Pettersson FE, Nilsson LN, et al: Docosahexaenoic acid stimulates non-amyloidogenic APP processing resulting in reduced Abeta levels in cellular models of Alzheimer's disease. Eur J Neurosci 2007; 26: 882-889.
27. Galasko D, Montine TJ: Biomarkers of oxidative damage and inflammation in Alzheimer's disease. Biomark Med 2010; 4: 27-436.
28. Musiek ES, Brooks JD, Joo M, et al: Electrophilic cyclopentenone neuroprostanes are anti-inflammatory mediators formed from the peroxidation of the omega-3 polyunsaturated fatty acid docosahexaenoic acid. J Biol Chem 2008; 283: 19927-19935.
29. Roberts LJ, Fessel JP, Davies SS: The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Brain Pathol 2005; 15: 143-148.
30. Chang GQ, Hao Y, Wong F: Apoptosis: final common pathway of photoreceptor death in rd, rds, and rhodopsin mutant mice. Neuron 1993; 11: 595-605.
31. Portera-Cailliau C, Sung CH, Nathans J, Adler R: Apoptotic photoreceptor cell death in mouse models of retinitis pigmentosa. Proc Natl Acad Sci USA 1994; 91: 974-978.
32. Papermaster DS: The birth and death of photoreceptors: the Friedenwald Lecture. Invest Ophthalmol Vis Sci 2002; 43: 1300-1309.
33. Bird AC: The Bowman lecture. Towards an understanding of age-related macular disease. Eye 2003; 17: 457-466.
34. Cideciyan AV, Aleman TS, Swider M, et al: Mutations in ABCA4 result in accumulation of lipofucsin before slowing the retinoid cycle: a reappraisal of the human disease sequence. Hum Mol Genet 2004; 13: 525-534.
35. Dryja TP, McGee TL, Reichel E, et al: A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature 1990; 343: 364-366.
36. Liu Q, Zuo J, Pierce EA: The retinitis pigmentosa 1 protein is a photoreceptor microtubule-associated protein. J Neurosci 2004; 24: 6427-6436.
37. Mendes HF, van der Spuy J, Chapple JP, Cheetham ME: Mechanisms of cell death in rhodopsin retinitis pigmentosa: implications for therapy. Trends Mol Med 2005; 11: 177-185.
38. Chong NH, Keonin J, Luthert PJ, et al: Decrease thickness and integrity of the macular elastic layer of Bruch's membrane correspond to the distribution of lesions associated with age-related macular degeneration. Am J Pathol 2005; 166: 241-251.
39. Hageman GS, Anderson DH, Johnson LV, et al: A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005; 102: 7227-7232.
40. Gold B, Merriam JE, Zernant J, et al: Variation in factor B (BF) and complement 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 2006; 38: 458-462.
41. Bok D: Evidence for an inflammatory process in age-related macular degeneration gains new support. Proc Natl Acad Sci USA 2005; 102: 7053-7054.
42. Sreekumar PG, Kannan R, Yaung J, et al: Protection from oxidative stress by methionine sulfoxide reductases in RPE cells. Biochem Biophys Res Commun 2005; 334: 245-253.
43. Feher J, Kovacs I, Artico M, et al: Mitochondrial alterations of retinal pigment epithelium in age-related macular degeneration. Neurobiol Aging 2006; 27: 983-993.
44. Sheets KG, Zhou Y, Ertel MK, et al: Neuroprotectin D1 attenuates laser-induced choroidal neovascularization in mouse. Mol Vis 2010; 16: 320-329.
45. Gamoh S, Hashimoto M, Sugioka K, et al: Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience 1999; 93: 237-241.
46. McGahon BM, Martin DS, Horrobin DF, Lynch MA: Age-related changes in synaptic function: analysis of the effect of dietary supplementation with omega-3 fatty acids. Neuroscience 1999; 94: 305-314.
47. Rodriguez de Turco EB, Belayev L, Liu Y, et al: Systemic fatty acid responses to transient focal cerebral ischemia: influence of neuroprotectant therapy with human albumin. J Neurochem 2002; 83: 515-524.
48. Belayev L, Marcheselli VL, Khoutorova L, et al: Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection. Stroke 2005; 36: 118-123.
49. Serhan CN, Gotlinger K, Hong S, et al: Antiinflammatory actions of neuroprotectin D1/ protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J Immunol 2006; 176: 1848-1859.
50. Mukherjee PK, Chawla A, Loayza MS, Bazan NG: Docosanoids are multifunctional regulators of neural cell integrity and fate: significance in aging and disease. Prostaglandins Leukot Essent Fatty Acids 2007; 77: 233-238.
51. Masukawa LM, Higashima M, Kim JH, Spencer DD: Epileptiform discharges evoked in hippocampal brain slices from epileptic patients. Brain Res 1989; 493: 168-174.
52. Schwartzkroin PA: Hippocampal slices in experimental and human epilepsy. Adv Neurol 1986; 44: 991-1010.
53. Williamson A, Patrylo PR, Pan J, et al: Correlations between granule cell physiology and bioenergetics in human temporal lobe epilepsy. Brain 2005; 128: 1199-1208.
54. Umeoka S, Terada K, Baba K, et al: Neural connection between bilateral basal temporal regions: cortico-cortical evoked potential analysis in patients with temporal lobe epilepsy. Neurosurgery 2009; 64: 847-855.
55. Birkle DL, Bazan NG: Effect of bicucullineinduced status epilepticus on prostaglandins and hydroxyeicosatetraenoic acids in rat brain subcellular fractions. J Neurochem 1987; 48: 1768-1778.
56. Champeil-Potokar G, Chaumontet C, Guesnet P, et al: Docosahexaenoic acid (22: 6n-3) enrichment of membrane phospholipids increases gap junction coupling capacity in cultured astrocytes. Eur J Neurosci 2006; 24: 3084-3090.
57. Poling JS, Vicini S, Rogawski MA, Salem N Jr: Docosahexaenoic acid block of neuronal voltage-gated K + channels: subunit selective antagonism by zinc. Neuropharmacology 1996; 35: 969-982.
58. Xiao Y, Li X: Polyunsaturated fatty acids modify mouse hippocampal neuronal excitability during excitotoxic or convulsant stimulation. Brain Res 1999; 846: 112-121.
59. Young C, Gean PW, Wu SP, et al: Cancellation of low-frequency stimulation-induced long-term depression by docosahexaenoic acid in the rat hippocampus. Neurosci Lett 1998; 247: 198-200.
60. Young C, Gean PW, Chiou LC, Shen YZ: Docosahexaenoic acid inhibits synaptic transmission and epileptiform activity in the rat hippocampus. Synapse 2000; 37: 90-94.
61. Cole-Edwards KK, Musto AE, Bazan NG: c-Jun N-terminal kinase activation responses induced by hippocampal kindling are mediated by reactive astrocytes. J Neurosci 2006; 26: 8295-8304.
62. Morimoto K, Fahnestock M, Racine RJ: Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog Neurobiol 2004; 73: 1-60.
63. Sutula T, Koch J, Golarai G, et al: NMDA receptor dependence of kindling and mossy fiber sprouting: evidence that the NMDA receptor regulates patterning of hippocampal circuits in the adult brain. J Neurosci 1996; 16: 7398-7406.
64. Taha AY, Bunham WM, Auvin S: Polyunsaturated fatty acid and epilepsy. Epilepsia 2010; 5: 1348-1358.